Table III.

Multivariate Analysis Results

Non-relapse mortality
	N	HR	95% CI Lower Limit	95% CI Upper Limit	P-value
Chemosensitivity
CR	173	1
PR	192	1.01	0.69	1.48	0.97
Chemoresistant	104	1.86	1.23	2.81	0.003
Conditioning Regimen (≤10 months)
RIC/NMA	368	1
MA	126	1.99	1.34	2.95	0.001
Conditioning Regimen (>10 months)
RIC/NMA	177	1
MA	47	0.59	0.25	1.39	0.23
Type of Donor
HLA-identical sibling	245	1
Well-matched/partially matched	249	1.44	1.04	2.00	0.03
Progression/Relapse
KPS
80–100	388	1
<80	51	1.81	1.18	2.77	0.006
Chemosensitivity
CR	173	1
PR	192	1.36	0.95	1.96	0.09
Chemoresistant	104	2.25	1.51	3.36	<0.0001
Time from autoHCT to alloHCT (≤1 year from HCT)
≥12 months between auto & allo	294	1
<12 months between auto & allo	200	2.28	1.66	3.14	<0.0001
Time from autoHCT to alloHCT (>1year from HCT)
≥12 months between auto & allo	146	1
<12 months between auto & allo	66	0.51	0.20	1.25	0.14
Progression free survival
KPS
80–100	388	1
<80	51	1.79	1.29	2.48	0.0005
Chemosensitivity
CR	173	1
PR	192	1.14	0.88	1.49	0.31
Chemoresistant	104	2.04	1.53	2.73	<0.0001
Time from autoHCT to alloHCT
≥12 months between auto & allo	294	1
<12 months between auto & allo	200	1.32	1.06	1.64	0.01
Conditioning regimen
RIC/NMA	368	1
MA	126	1.29	1.02	1.63	0.03
Overall survival
KPS
80–100	393	1
<80	52	1.86	1.33	2.60	0.0003
Chemosensitivity
CR	175	1
PR	197	1.16	0.88	1.52	0.30
Chemoresistant	106	1.94	1.44	2.62	<0.0001
Conditioning Regimens
RIC/NMA	376	1
MA	127	1.39	1.09	1.78	0.008
Graft Type (≤3 months)
Bone marrow	47	1
Peripheral blood	456	0.37	0.22	0.61	<0.0001
Graft Type (>3 months)
Bone marrow	27	1
Peripheral blood	377	1.43	0.78	2.64	0.25

N = number; HR = hazard ratio; CI = confidence interval; CR = complete response; PR = partial response; RIC = reduced intensity conditioning; NMA = ; non-myeloablative conditioning MA = myeloablative conditioning; KPS = Karnofsky performance status; HLA = human leucocyte antigen; HCT = haematopoietic cell transplantation; alloHCT = allogeneic; auto = autologous.